Please note this programme is subject to change

We welcome abstracts on any subject relating to Diabetes, Endocrinology and General Medicine, which might be of interest to members of the Association. Authors of accepted abstracts will be invited to display their work in the form of a poster at the meeting on 7th November. Those meeting the criteria for publication will be published on the ABCD and BJD websites.

Two prizes will be awarded:

The ABCD & EASE Regional meeting will take place on Thursday 26th June at the UEA Research Park, Norwich. registration will open shortly for this event.

We would like to invite abstracts of not more than 250 words. We welcome abstracts from all members of the MDT, including students, and abstracts should be related to care of patients with diabetes or endocrinological illness. Authors of the top four scoring abstracts will be invited to present at the meeting.

Ahead of the JBDS-IP Inpatient Diabetes Conference taking place on 13th June in Liverpool, we are interested in abstract submissions in innovations and interventions in inpatient diabetes as well as interventions that did not go to plan in order to learn from. (250 words). Examples include but not exclusive to:

Many clinicians all over the country are engaged in highly innovative and impactful work in the field of diabetes.

Help us to recognise a young and innovative researcher. Please share this work and nominate yourself or someone else for a ‘rising star’ lecture at the ABCD Annual Conference 2025

Submissions are invited from ABCD members for this named lecture at the forthcoming ABCD Conference in November 2025 which I hope you will attend.

There were three posters from the ABCD audit programme presented at the Diabetes UK annual professional conference at SEC, Glasgow, 26-28 February 2025.

In a poster from the Worldwide Audit of Testosterone Deficiency in Men with Type 2 Diabetes, Prof Hugh Jones showed that testosterone replacement therapy (TRT) improved symptoms and quality of life increasingly over at least 24 months. TRT also reduced HbA1c increasingly over a three year follow up period.

Join us for this valuable face to face conference as we focus on all things inpatient diabetes. 

Hear from our expert speakers who will provide in-depth insight and inform participants about the latest developments in how to introduce the latest innovations in inpatient diabetes care. 

By attending the conference, you will: 

Effectiveness of Semaglutide in Oral vs Subcutaneous Injectable Formulation: An analysis of UK Real-world Data in the Association of British Clinical Diabetologists (ABCD) national audit

Endoscopic Duodenal-jejunal Bypass Liner treatment for Type 2 Diabetes and Obesity: A comparison of the outcomes with an implantation period of 6 months versus 12 months in a worldwide registry